Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain

URN to cite this document:: urn:nbn:de:bvb:355-epub-530729
DOI to cite this document:: 10.5283/epub.53072

Blazquez, Raquel ; Chuang, Han-Ning ; Wenske, Britta ; Trigueros, Laura ; Wlochowitz, Darius ; Liguori, Renato

; Ferrazzi, Fulvia ; Regen, Tommy ; Proescholdt, Martin A. ; Rohde, Veit ; Riemenschneider, Markus J. ; Stadelmann, Christine ; Bleckmann, Annalen ; Beißbarth, Tim ; van Rossum, Denise ; Hanisch, Uwe K. ; Pukrop, Tobias

License: Creative Commons Attribution 4.0
PDF - Published Version
(6MB)

Date of publication of this fulltext: 20 Oct 2022 05:37

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Indexed in

Export bibliographical data

Abstract

Brain metastasis in breast cancer remains difficult to treat and its incidence is increasing. Therefore, the development of new therapies is of utmost clinical relevance. Recently, toll-like receptor (TLR) 4 was correlated with IL6 expression and poor prognosis in 1 215 breast cancer primaries. In contrast, we demonstrated that TLR4 stimulation reduces microglia-assisted breast cancer cell ...